Neurocrine’s Phase II Results In Schizophrenia Mixed, But Enough To Move To Phase III

 
• By Joseph Haas
  
PS1911_Clinical Trial_1444423208_1200.jpg
Neurocrine's Phase II schizophrenia trial yielded signs of efficacy but mixed results
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D